UNITY is on track to receive 24-week topline data from its Phase 2b ASPIRE study in diabetic macular edema this quarter, which could provide critical insights for future trials. UBX1325 (foselutoclax) ...
SAN FRANCISCO, March 07, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UBX) (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, ...
Unity Software (U) is back in focus after several firms reiterated positive ratings and raised their outlook, with an overall Outperform consensus that appears linked to the stock’s recent move. See ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback